PANDAS Diagnosis and Treatment Approach

Introduction to PANDAS

The American Heart Association states that PANDAS should be considered only as a yet-unproven hypothesis, and carefully designed studies have not established a causal relationship between streptococcal infections and these neuropsychiatric symptoms 1, 2
The concept of PANDAS was proposed in 1998, suggesting that childhood obsessive-compulsive disorder and/or tics may arise from post-streptococcal autoimmune processes similar to Sydenham chorea 1, 2

The American Academy of Family Physicians recommends treating acute streptococcal pharyngitis with standard 10-day antibiotic regimens, such as penicillin V, amoxicillin, or benzathine penicillin G IM 3, 4, 5
For non-immediate allergy (delayed rash), the Infectious Diseases Society of America recommends cephalexin or cefadroxil as alternative treatments 4, 5
For immediate/anaphylactic allergy (avoid all beta-lactams), the Infectious Diseases Society of America recommends clindamycin, azithromycin, or clarithromycin as alternative treatments 4, 5

If a child presents with new-onset OCD or tics after strep throat, the American Heart Association recommends treating any documented acute streptococcal pharyngitis with standard 10-day antibiotic regimens 3, 4, 5
The American Heart Association also recommends referring the child to pediatric neurology and/or psychiatry for evaluation and management of the neuropsychiatric symptoms with standard therapies for OCD/tic disorders 1, 2

The American Heart Association advises against prescribing long-term prophylactic antibiotics for presumed PANDAS without documented recurrent streptococcal infections, as this lacks evidence and promotes resistance 1, 2
The American Heart Association also advises against ordering extensive streptococcal testing (serial ASO titers, anti-DNase B) to diagnose or manage PANDAS, as this is not recommended 1, 2
The Infectious Diseases Society of America recommends avoiding aspirin in children due to Reye syndrome risk 4, 5

The 2020 American Gastroenterological Association (AGA) guidelines make no recommendations for the use of probiotics in neuropsychiatric, autoimmune, or streptococcal‑related disorders such as PANS/PANDAS, reflecting insufficient or absent evidence to support such interventions. 6

The same AGA guidelines conditionally suggest the use of particular probiotic strains (e.g., Saccharomyces boulardii and selected Lactobacillus/Bifidobacterium formulations) for preventing antibiotic‑associated Clostridioides difficile infection, but do not endorse Streptococcus salivarius K12 for this purpose, indicating a low‑to‑moderate quality evidence base for the recommended strains and a lack of data for K12. 7

For most pediatric conditions, the AGA advises that probiotics should be employed only within the framework of clinical trials, underscoring the limited and heterogeneous evidence supporting routine probiotic therapy in children. This reflects a cautious, evidence‑based stance pending higher‑quality research. 6